A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
Trial details
- Registry ID
- NCT05630183
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as AGEN1181
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Botensilimab in Participants With Metastatic Pancreatic CancerNCT05630183 | AGEN | Phase 2 | Completed | 2026-01-05Actual |
| A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerNCT05608044 | AGEN | Phase 2 | Active not recruiting | 2027-09Estimated |
| A Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaNCT05529316 | AGEN | Phase 2 | Terminated | 2026-04-27Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |